Endpoints News

August 1, 2024

With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies

Seattle startup Outpace Bio, a Lyell Immunopharma spinout using AI to design proteins for solid tumor cell therapies, has raised a $144 million Series B to gather clinical data from its first two programs.

Outpace in the Press

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

November 19, 2024

Publications

Society for Immunotherapy of Cancer (SITC)

DOWNLOAD

Publications

November 5, 2024

Public Relations

Globe Newswire

Outpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

DOWNLOAD

PR

August 1, 2024

In The News

GeekWire

Protein design startup Outpace lands $144M to test treatments that target solid tumors

DOWNLOAD

News

August 1, 2024

In The News

synbiobeta

AI-Driven Cell Therapy Pioneer Outpace Bio Raises $144M in Series B Funding

DOWNLOAD

News

August 1, 2024

In The News

Endpoints News

With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies

DOWNLOAD

News

August 1, 2024

Public Relations

Globe Newswire

Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development

DOWNLOAD

PR

April 7, 2024

Publications

American Association for Cancer Research (AACR)

OPB-101: An optimized mesothelin-specific CAR T cell product expressing CD8-targeted IL-2/15 and engineered to resist T cell exhaustion

DOWNLOAD

Publications

April 7, 2024

Publications

American Association for Cancer Research (AACR)

"Development of tumor-restricted IL-12 with antigen-dependent expression and localized IL-12 activity"

DOWNLOAD

Publications

All

November 19, 2024

Publications

Society for Immunotherapy of Cancer (SITC)

Publications

November 5, 2024

Public Relations

Globe Newswire

Outpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

PR

August 1, 2024

In The News

GeekWire

Protein design startup Outpace lands $144M to test treatments that target solid tumors

News

August 1, 2024

In The News

synbiobeta

AI-Driven Cell Therapy Pioneer Outpace Bio Raises $144M in Series B Funding

News

August 1, 2024

In The News

Endpoints News

With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies

News

August 1, 2024

Public Relations

Globe Newswire

Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development

PR

August 1, 2024

In The News

GeekWire

Protein design startup Outpace lands $144M to test treatments that target solid tumors

News

August 1, 2024

In The News

synbiobeta

AI-Driven Cell Therapy Pioneer Outpace Bio Raises $144M in Series B Funding

News

August 1, 2024

In The News

Endpoints News

With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies

News

August 2, 2023

In The News

GeekWire

Seattle startups move into growing science cluster in South Lake Union

News

July 10, 2023

In The News

GeekWire

How AI is changing the way scientists engineer drugs, biosensors, enzymes and more

News

May 26, 2023

In The News

Endpoints News

Outpace Bio expands cell therapy R&D, nets research collaborations in Seattle

News

November 5, 2024

Public Relations

Globe Newswire

Outpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

PR

August 1, 2024

Public Relations

Globe Newswire

Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development

PR

April 4, 2024

Public Relations

Globe Newswire

Outpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual Meeting

PR

October 31, 2023

Public Relations

Globe Newswire

Outpace Bio to present new data on tumor-restricted IL-12 designed leveraging OutSmart technology to enhance solid tumor T cell therapies at SITC 2023

PR

May 22, 2023

Public Relations

Globe Newswire

Outpace Bio expands Seattle presence with cell therapy research hub & collaborations with leading experts in protein design & cancer immunotherapy

PR

May 18, 2023

Public Relations

Globe Newswire

Outpace Bio to present new data on OutSmart™ IL-2/15, a CAR T cell-produced designed cytokine with tumor-localized immune cell activity, at the 2023 annual meeting of the American Society of Gene & Cell Therapy (ASGCT)

PR

November 19, 2024

Publications

Society for Immunotherapy of Cancer (SITC)

Publications

April 7, 2024

Publications

American Association for Cancer Research (AACR)

OPB-101: An optimized mesothelin-specific CAR T cell product expressing CD8-targeted IL-2/15 and engineered to resist T cell exhaustion

Publications

April 7, 2024

Publications

American Association for Cancer Research (AACR)

"Development of tumor-restricted IL-12 with antigen-dependent expression and localized IL-12 activity"

Publications

April 7, 2024

Publications

American Association for Cancer Research (AACR)

In vitro modeling of antigen-driven exhaustion in human CAR T cells

Publications

November 3, 2023

Publications

Society for Immunotherapy of Cancer (SITC)

Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies

Publications

October 9, 2023

Publications

Cancer Cell

Building smart CAR T cell therapies: The path to overcome current challenges

Publications

Press Kit

The Outpace Press Kit is designed to help journalists research Outpace. Please contact our communications team if you need more information or to schedule an interview.

Download

With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies

Outpace in the Press

Press Kit

Connect With Us